APA (7th ed.) Citation

W, L., DK, K., CB, S., HK, L., S, P., DS, J., . . . KH, P. (2022). Incorporation of SKI-G-801, a Novel AXL Inhibitor, With Anti-PD-1 Plus Chemotherapy Improves Anti-Tumor Activity and Survival by Enhancing T Cell Immunity. Frontiers in oncology, 12, 821391. https://doi.org/10.3389/fonc.2022.821391

Chicago Style (17th ed.) Citation

W, Lee, et al. "Incorporation of SKI-G-801, a Novel AXL Inhibitor, With Anti-PD-1 Plus Chemotherapy Improves Anti-Tumor Activity and Survival by Enhancing T Cell Immunity." Frontiers in Oncology 12 (2022): 821391. https://doi.org/10.3389/fonc.2022.821391.

MLA (9th ed.) Citation

W, Lee, et al. "Incorporation of SKI-G-801, a Novel AXL Inhibitor, With Anti-PD-1 Plus Chemotherapy Improves Anti-Tumor Activity and Survival by Enhancing T Cell Immunity." Frontiers in Oncology, vol. 12, 2022, p. 821391, https://doi.org/10.3389/fonc.2022.821391.